NovaBridge Biosciences (NBP)
NASDAQ:NBP
NBP Analyst Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
NBP Stock 12 Month Forecast
Average Price Target
$9.00
▲(262.90% Upside)
| Highest Price Target$9.00 | Average Price Target$9.00 | Lowest Price Target$9.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$9
Buy
262.90%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Sanofi (Other OTC: SNYNF)Valuation and risks to reaching our price target. Our price target of $9.00 is based on an equally weighted composite of: (a) $10.08/share, as a 18x multiple of taxed and diluted $1.39 discounted back to and (b) an NPV of $7.4/share (discounted cash flow analysis using a 12.0% discount rate and 3.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks. H.C. WAINWRIGHT & CO.
BTIG
$9
Buy
262.90%
Upside
Reiterated
01/06/26
Leerink Partners
$9
Buy
262.90%
Upside
Initiated
10/06/25
Brookline Capital Markets
$6→$8
Buy
222.58%
Upside
Reiterated
08/28/25
Lucid Capital
$5
Buy
101.61%
Upside
Initiated
05/28/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$9
Buy
262.90%
Upside
Reiterated
04/08/26
Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Sanofi (Other OTC: SNYNF)Valuation and risks to reaching our price target. Our price target of $9.00 is based on an equally weighted composite of: (a) $10.08/share, as a 18x multiple of taxed and diluted $1.39 discounted back to and (b) an NPV of $7.4/share (discounted cash flow analysis using a 12.0% discount rate and 3.0% growth rate, in line with the expected discount and growth parameters of an early development-stage biotechnology company). Risks to achieving our price target include regulatory, commercial, clinical development, manufacturing, financial, liability and intellectual property risks. H.C. WAINWRIGHT & CO.
BTIG
$9
Buy
262.90%
Upside
Reiterated
01/06/26
Leerink Partners
$9
Buy
262.90%
Upside
Initiated
10/06/25
Brookline Capital Markets
$6→$8
Buy
222.58%
Upside
Reiterated
08/28/25
Lucid Capital
$5
Buy
101.61%
Upside
Initiated
05/28/25
Best Analysts Covering NovaBridge Biosciences
3 Months
xxx
Success Rate
4/8 ratings generated profit
Average Return
+70.10%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +70.10% per trade.
1 Year
Success Rate
3/8 ratings generated profit
Average Return
+13.95%
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 37.50% of your transactions generating a profit, with an average return of +13.95% per trade.
2 Years
xxx
Success Rate
3/8 ratings generated profit
Average Return
+13.95%
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +13.95% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
NBP Analyst Recommendation Trends
Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
3
1
2
4
4
Buy
2
0
0
0
0
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
1
2
4
4
Each month's total comprises the sum of three months' worth of ratings.
NBP Financial Forecast
NBP Stock Forecast FAQ
What is NBP’s average 12-month price target, according to analysts?
Based on analyst ratings, NovaBridge Biosciences’s 12-month average price target is 9.00.
What is NBP’s upside potential, based on the analysts’ average price target?
NovaBridge Biosciences has 262.90% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is NBP a Buy, Sell or Hold?
NovaBridge Biosciences has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is NovaBridge Biosciences’s price target?
The average price target for NovaBridge Biosciences is 9.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 262.90% Increase from the current price of $2.48.
The highest analyst price target is $9.00 ,the lowest forecast is $9.00. The average price target represents 262.90% Increase from the current price of $2.48.
What do analysts say about NovaBridge Biosciences?
NovaBridge Biosciences’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
How can I buy shares of NBP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.